Kezar Life Sciences Inc
$ 7.38
0.27%
15 Apr - close price
- Market Cap 54,254,000 USD
- Current Price $ 7.38
- High / Low $ 7.39 / 7.34
- Stock P/E N/A
- Book Value 9.56
- EPS -7.60
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -0.60 %
- 52 Week High 7.55
- 52 Week Low 3.53
About
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, is dedicated to the discovery and development of new small molecule therapies to address the unmet needs in immune-mediated diseases and cancer in the United States. The company is headquartered in South San Francisco, California.
Analyst Target Price
$6.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-30 | 2025-11-12 | 2025-08-13 | 2025-06-18 | 2025-03-12 | 2024-11-13 | 2024-08-13 | 2024-05-09 | 2024-03-14 | 2023-11-13 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -1.0536 | -1.53 | -1.87 | -2 | -3 | -2.78 | -0.27 | -0.3 | -0.44 | -0.32 | -0.34 | -0.31 |
| Estimated EPS | -1.31 | -0.26 | -0.28 | -2.65 | -2.76 | -3.15 | -0.32 | -0.33 | -0.38 | -0.35 | -0.32 | -0.29 |
| Surprise | 0.2564 | -1.27 | -1.59 | 0.65 | -0.24 | 0.37 | 0.05 | 0.03 | -0.06 | 0.03 | -0.02 | -0.02 |
| Surprise Percentage | 19.5725% | -488.4615% | -567.8571% | 24.5283% | -8.6957% | 11.746% | 15.625% | 9.0909% | -15.7895% | 8.5714% | -6.25% | -6.8966% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.98 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KZR
2026-04-14 09:39:18
Kezar Life Sciences (NASDAQ: KZR) is set to be acquired by Aurinia for $6.955 per share in cash, plus a Contingent Value Right (CVR). The CVR offers stockholders potential additional cash payments based on future milestones, including excess net cash, proceeds from existing agreements, and success in developing Legacy Assets, particularly zetomipzomib. Kezar's board unanimously recommended the offer after a comprehensive strategic review process.
2026-04-13 11:09:34
Aurinia Pharma U.S., Inc. is undertaking a tender offer to acquire all outstanding common shares of Kezar Life Sciences, Inc. for $6.955 per share in cash plus one nontransferable contingent value right (CVR) per share. The acquisition is being effected through an Agreement and Plan of Merger dated March 30, 2026. As of April 10, 2026, there were 7,387,701 Kezar shares outstanding, and the deal is not subject to a financing condition.
2026-04-12 19:09:34
This article focuses on the working capital per share of Kezar Life Sciences Inc, traded as FWB:2KZ0 on the Frankfurt Stock Exchange. It appears to be a financial data snippet from TradingView, indicating that the market was closed at the time of publication and providing links to various financial metrics and tools related to the company.
2026-04-12 19:09:05
This article provides financial data for Kezar Life Sciences Inc (FWB:2KZ0), specifically focusing on its tangible book value per share. It presents a basic data table with columns for "Period," "Value," "Change," and "Change %" for this metric. The content highlights that this information is available on TradingView, a platform offering various market data and analysis tools.
2026-04-12 12:09:05
This article provides a technical analysis of Kezar Life Sciences Inc (KZR), indicating a "Neutral" overall technical sentiment. Despite this, several moving averages suggest a "Buy" signal for KZR, whose current share price is $7.37. The analysis includes details on momentum indicators like RSI and MACD, support and resistance levels, and various moving averages.
2026-04-10 06:09:19
Kezar Life Sciences, Inc. (NASDAQ:KZR) has received an average "Reduce" recommendation from brokerages, with an average one-year target price of $6.00. The company reported wider-than-expected quarterly losses, missing analyst consensus earnings per share estimates, and analysts forecast a significant full-year EPS loss. Institutional investors hold a substantial portion of the thinly capitalized stock.
